2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium
Bruno François(Inserm), Hasan S. Jafri(AstraZeneca (Australia)), Filip Dubovsky(University of Maryland, Baltimore), Alexey Ruzin(AstraZeneca (United States)), Miguel Sánchez García(Hospital Clínico San Carlos), Cédric Bretonnière(Inserm), Frank E. J. Coenjaerts(Utrecht University), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Jérôme Pugin(University Hospital of Geneva), Kathryn Shoemaker(AstraZeneca (United States)), Ana Catalina Hernandez Padilla(Inserm), Susan Colbert(AstraZeneca (United States)), Philippe Eggimann(University Hospital of Lausanne), Pierre‐François Dequin(Université de Tours), Omar Ali(AstraZeneca (United States)), Michael McCarthy, Yuling Wu(AstraZeneca (United States)), Lucía Viña Soria(Hospital Universitario Central de Asturias), Thierry Boulain(Centre hospitalier universitaire d'Orléans), Vadryn Pierre(AstraZeneca (United States)), Vincent Huberlant(Centre Hospitalier Universitaire de Nantes)
Cited by 5
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976